SUBSCRIBE NOW

SIGHT

Be informed. Be challenged. Be inspired.

World Bank seeks board approval for $US12 billion coronavirus vaccine financing plan

Washington DC, US
Reuters

World Bank President David Malpass said on Tuesday he is seeking board approval for a $US12 billion coronavirus vaccine financing plan to help poor and developing countries secure a sufficient share of vaccine doses when they become available in the coming months.

Malpass told Reuters in an exclusive interview that the initiative, part of $US160 billion in coronavirus aid financing pledged by the multi-lateral lender, is aimed at helping countries procure and distribute vaccines early to healthcare and other essential workers and expand global production. He said the board was expected to consider the plan in early October.

David Malpass World Bank

World Bank Group President David Malpass attends a news conference after a meeting at the Chancellery in Berlin, Germany, on 1st October, 2019. PICTURE: Reuters/Hannibal Hanschke/File photo.

Global competition for early coronavirus vaccine doses is already fierce, months ahead of any approvals, as wealthy countries move to secure supplies. 

The US Government has pledged over $US3 billion to secure hundreds of millions of doses of vaccines under development by Britain’s AstraZeneca Plc and by US drug giant Pfizer Inc and Germany’s BioNTech SE.

Malpass said the World Bank plan aimed to put poor and middle-income countries, where the virus is spreading most rapidly, on the same footing as richer countries by ensuring they have financing to secure supplies and a system for distribution, which will encourage drugmakers to meet their demand. 

Without early doses that can bring outbreaks under control, many of these countries risk economic collapse that will push hundreds of millions of people back into poverty.

“Our goal is to alter the course of the pandemic for the low and middle income developing countries,” Malpass said. “This is a market signal to the manufacturers that there will be financing available for the developing countries and there will be demand. We will begin asking the manufacturers to begin creating allocations for these countries.”Malpass said the World Bank also was asking wealthy countries that have “over-reserved” more doses than they will ultimately need to release those doses to poorer countries.

He added that he is working to persuade countries that equitable distribution of vaccines “is important to the world and will give a better outcome for the world.”

Separately, Brent McIntosh, US Treasury under-secretary for international affairs, told a Foreign Policy magazine forum on Tuesday that wealthy countries were working on broad vaccine availability.

“There have been intense conversations among various developed countries on ensuring that there are vaccines available in the developing world and those conversations are ongoing at the highest levels,” said McIntosh, who oversees US involvement in the World Bank and the International Monetary Fund.

The World Bank program will disburse grant or loan funding to countries, and will be able to select any vaccine that meets safety criteria, including approval from multiple “highly respected, stringent regulatory agencies,” such as those in the United States, Canada, Japan and several European countries, Malpass said.

The World Bank’s private-sector arm, the International Financing Corp, in July launched a $US4 billion financing platform to boost investment in developing country production of vaccines and other critical health products. 

 

Donate



sight plus logo

Sight+ is a new benefits program we’ve launched to reward people who have supported us with annual donations of $26 or more. To find out more about Sight+ and how you can support the work of Sight, head to our Sight+ page.

Musings

TAKE PART IN THE SIGHT READER SURVEY!

We’re interested to find out more about you, our readers, as we improve and expand our coverage and so we’re asking all of our readers to take this survey (it’ll only take a couple of minutes).

To take part in the survey, simply follow this link…

Leave a Reply

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.